Neutral
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com
Cantor Fitzgerald has reiterated an Overweight rating on Summit Therapeutics (NASDAQ:SMMT) despite concerns regarding the HARMONi-3 trial results for ...